Each of our portfolio of eight novel, clinical-stage drug candidates has the potential to become a best-in-class or first-in-class treatment for patients.
China has emerged as the second-largest pharmaceutical market in the world, where a growing patient population, significant unmet medical needs, new regulatory reforms and expanding reimbursement are driving demand for high quality, innovative medicines.
Everest Medicines is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies with the mission of addressing critical unmet medical needs in Greater China and other emerging Asia Pacific markets.
We are committed to highest quality, integrity and excellence in how we conduct our business and achieve our goals.
We are united by our purpose to improve lives with our innovative medicines.
Since our inception in 2017, we have assembled an experienced and visionary management team, and in-licensed eight late-stage drug candidates in four major therapeutic areas: oncology, immunology, cardio-renal disease and infectious disease.
Read More
